Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSVI-301
- Development stage
- Unknown
- Lead developer
- RosVivo Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Covalent Small Molecules → Small Molecules, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Classical Binding Small Molecules → Small Molecules
- Administration
- Subcutaneous
01
Overview
**RSVI-301** is a first-in-class miRNA-based therapeutic developed by RosVivo Therapeutics as an inhibitor of miR-10b (specifically targeting miR-10b-5p), functioning as an epigenetic modulator to address the root causes of type 2 diabetes (T2D) and related metabolic conditions. It restores pancreatic beta cell function for insulin secretion, reduces insulin resistance, and demonstrates efficacy in preclinical animal models for obesity, fatty liver (NAFLD), and gastrointestinal disorders, with advantages over GLP-1 receptor agonists including lower injection frequency, prolonged effects, and reduced side effects like GI dysmotility. Collaboration with Eli Lilly via MTA confirmed superior preclinical data, and it is positioned for potential expansion to COVID-19 treatment.[1][3][5][7][9]
- Other names
- miR-10b mimicmiR10b mimicmiR 10b mimicmiR-10b-5p mimicmiR10b-5p mimicmiR 10b-5p mimicmicroRNA-10b mimicmicroRNA10b mimicmicroRNA 10b mimicsynthetic miR-10bsynthetic miRNA-10b
02
Targets
KLF11KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on RSVI-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSVI-301.